New research indicates that individuals who discontinue new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who end traditional diet and exercise programs.
Findings released in a major medical journal shows that while overweight individuals frequently drop a large proportion of their total mass while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month after stopping.
"Users buying these treatments need to be aware of the danger of quick rebound weight gain when the treatment concludes," warns lead investigator Dr. Susan Jebb.
This pace of recovery suggests a return to pre-treatment weight in about 18 months.
Weighing Therapies
The research, which examined dozens of trials involving thousands of participants, compared the outcomes of these new drugs with conventional dieting.
Researchers note that individuals who lose weight through diet and exercise generally experience a more gradual weight regain—approximately 100 grams monthly—after stopping.
Understanding the Fast Rebound
Nutrition scientists believe the mode of action of the jabs accounts for the heightened rebound.
These medications mimic a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than normal might result in the system to generate a reduced amount of its own natural hormone, and may also lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication leads to hunger is no longer kept in check, making binge eating far more likely."
A Chronic Condition?
Medical guidelines advise the jabs for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Many experts contend that, given the significant potential of relapse, the therapy is often long-term.
This perspective is echoed by drug manufacturers, who note that the results "emphasize the long-term nature of excess weight," similar to managing diseases like diabetes.
Patient Experiences
People who have come off the jabs explain a sudden return of hunger.
"I experienced something that goes on and I was suddenly starving," described a patient.
This difficulty is worsened if users have not adopted permanent lifestyle or habit changes during therapy.
Growing Interest
Recent estimates indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.
- Use is greater among females than men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, clinicians stress that while the jabs are potent tools for weight loss, they are not a permanent fix and long-term success hinges on combined lifestyle support.
